VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results highlight its potential to address a major limitation of conventional ADCs—off-target toxicity that can damage healthy tissues. By activating therapeutic effects only in targeted tumor cells, the BiTAC approach aims to widen the therapeutic window and improve patient outcomes.
VERAXA’s proprietary BiTAC platform is designed to enhance the precision of antibody-based cancer therapies. The company maintains a diversified oncology pipeline of antibody-based formats, including ADCs, T-cell engagers (TCEs), and other antibody-based formats. The BiTAC-ADC platform represents a next-generation ADC that incorporates a conditionally active mechanism, potentially reducing systemic side effects.
In addition to the BiTAC-ADC data, VERAXA is also presenting its BiTAC-TCE platform for potential strategic collaborations at the BIO International Convention. The company’s focus on improving cancer therapy selectivity aligns with broader industry trends toward more targeted and less toxic treatments.
VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The listing provides the company with access to capital markets to advance its pipeline. Investors can find the latest news and updates relating to VRXA in the company’s newsroom at https://nnw.fm/VRXA.
The in vitro proof-of-concept data mark an important milestone for VERAXA, but the BiTAC-ADC platform remains in early development. Further preclinical studies and eventual clinical trials will be necessary to validate the technology’s safety and efficacy. Nonetheless, the ability to selectively target cancer cells while sparing healthy tissue could represent a significant advancement in oncology, potentially reducing the severe side effects associated with many current chemotherapies and targeted agents.
